SecProbe.io

CORRESP
1
filename1.htm

90
Park Avenue

New
York, NY 10016

212-210-9400
| Fax: 212-210-9444

    Matthew
    W. Mamak
    Direct
    Dial: 212-210-1256
    Email:
    matthew.mamak@alston.com

February
27, 2020

    Ms.
        Lisa Vanjoske

        Mr.
        Daniel Gordon

        Division
        of Corporation Finance

        Office
        of Life Sciences

U.S. Securities & Exchange Commission

 100 F Street, NE Washington, D.C. 20549

    Re:
    OncoSec
        Medical Inc.

        Form
10-K for the fiscal year ended July 31, 2019 filed October 28, 2019

        Form
10-Q for the quarterly period ended October 31, 2019 filed December 13, 2019

        File
        No. 000-54318

Dear
Ms. Vanjoske and Mr. Gordon:

At
the request and on behalf of our client, OncoSec Medical Incorporated, (the “Company”), we hereby submit the following
response to the comment of the Staff of the Securities and Exchange Commission (the “Staff”) received on February
13, 2020 by the Company (the “Request Letter”), related to the Company’s Form 10-K and Form 10-Q noted above.
Our response is as follows and has been prepared by the Company with our assistance.

SEC
Comment:

You
disclose “Whether or not Closing occurs, but subject to certain conditions on effectiveness described above, the Company
(1) will grant CGP and its affiliates an exclusive license to develop, manufacture, commercialize, or otherwise exploit current
and future products, including TAVO and the VLA in the Territory for which CGP will pay the Company up to 20% royalties on the
net sales of such products in the Territory.” Please disclose the royalty rate or a range that does not exceed a 10-point
range. Also disclose the minimum royalty and termination provisions specified in the agreement.

Company
Response:

Please
note that the Company made the decision to exclude the minimum royalty percentage, as filed on Form 8-K as Exhibit 10.3
on October 11, 2019, on the basis that such information is (i) not material and (ii) would be competitively harmful if publicly
disclosed.

www.alston.com

Atlanta
| Beijing | Brussels | Charlotte | Dallas | Los Angeles | New York | Research Triangle | San Francisco | Silicon Valley | Washington,
D.C.

February
27, 2020

Page
2

In
response to the Staff’s comment, beginning in the Company’s Form 10-Q for the period ended January 31, 2020, the Company
proposes to include the following additional disclosure, where applicable, regarding the termination provisions under the License
Agreement, substantially in the form below.

License
Agreement and Services Agreement

Concurrently
with the execution and delivery of the Purchase Agreements, the Company and CGP entered into a License Agreement (the “License
Agreement”), which became effective upon the Closing. Pursuant to the License Agreement, the Company, among other things,
granted CGP and its affiliates an exclusive, sublicensable, royalty-bearing license to develop, manufacture, commercialize, or
otherwise exploit the Company’s current and future products, including TAVO and the VLA in the following territories: China
Mainland, Hong Kong, Macau, Taiwan, Armenia, Azerbaijan, Bahrain, Bangladesh, Bhutan, Brunei, Burma, Cambodia, East Timor, Georgia,
India, Indonesia, Jordan, Kazakhstan, Kuwait, Kyrgyzstan, Laos, Malaysia, Mongolia, Nepal, Oman, Pakistan, Papua New Guinea, Philippines,
Qatar, Saudi Arabia, Singapore, South Korea, Sri Lanka, Tajikistan, Thailand, Turkmenistan, United Arab Emirates, Uzbekistan and
Vietnam (the “Territory”). Under the terms of the License Agreement, CGP will pay the Company up to 20% royalties
on the net sales (as defined in the License Agreement) of such products in the Territory during the applicable Royalty Term (as
defined in the License Agreement).

In
addition, the Company and Sirtex entered into a Services Agreement (the “Services Agreement”) which became effective
upon the Closing. Pursuant to the Services Agreement, the Company agreed, among other things, to pay Sirtex low single-digit royalties
on the Net Sales (as defined in the Services Agreement) of all Products (defined as TAVO and VLA products and their accompanying
generators, and any products (including, for clarity, combination products) incorporating or including such products and their
accompanying generators), in all countries other than those in the Territory. In exchange for the royalty fee, Sirtex will provide
the Company with certain services for these products, including key opinion leader management and engagement services, voice of
customer (VOC) services, development of a go to market strategy, and pricing, reimbursement and market access services.

If
either party believes that the other party has materially breached one or more of its material obligations under the License Agreement,
then the non-breaching party may, following a cure period, terminate the License Agreement upon written notice to the breaching
party, subject to other conditions. Licensee may terminate the License Agreement in its entirety for any reason or no reason upon
prior written notice to Licensor. Additionally, the License Agreement may be terminated upon certain events involving bankruptcy
or insolvency. If CGP terminates the License Agreement for convenience or the Company terminates the License Agreement due to
CGP’s breach or insolvency, then, subject to certain conditions, each party’s rights and licenses will terminate,
and CGP will have certain obligations to assign to the Company, or grant a right of reference under, certain regulatory documentation
or approvals. If CGP terminates the License Agreement due to the Company’s breach or insolvency, then CGP will have the
option either to keep the License Agreement in effect with the royalty rate owed by CGP to the Company reduced by 50% or to terminate
the License Agreement (in which case each party’s rights and licenses will terminate, except that CGP will have the right
to wind down certain clinical trials).

*
* *

If
you have any questions or require further assistance, please do not hesitate to contact me.

    Very
    truly yours,

    /s/
    Matthew W. Mamak

    Matthew
    W. Mamak

    CC:

    Daniel
    J. O’Connor, Chief Executive Officer and President

    OncoSec
    Medical Incorporated

    Robert
    J. DelAversano, Principal Accounting Officer and Controller

    OncoSec
    Medical Incorporated